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The 20th anniversary of the first human application of percu-
taneous transluminal coronary angioplasty (PTCA) was cele-
brated in 1997 (1). During this brief lifetime, catheter-based
revascularization has seen tremendous growth, expanding in-
dications and dramatic technologic improvements. PTCA is
now accepted as an effective therapy, with hundreds of thou-
sands of procedures performed annually in the United States
alone. However, timely, objective comparisons of PTCA, by-
pass surgery and medical therapy as options for patients with
coronary artery disease have been limited. Although random-
ized trials have demonstrated that PTCA has a role in relieving
anginal symptoms (2), is comparable to operation for multives-
sel disease in selected patients (3,4) and can serve to provide
effective reperfusion in the setting of acute myocardial infarc-
tion (5–7), such important clinical data often reach publication
when advancing technologies have made their relevance to
modern practice unclear. Data on new devices are often from
single-center, single-device reports that cannot agree on out-
comes, such as “success” and “restenosis,” making compari-
sons problematic. Thus, patient selection and appropriate
technique application for percutaneous coronary revascular-
ization remains a case by case challenge.
Registry data have been key elements in the field of
interventional cardiology in the documentation of strategy and
outcome. The National Heart, Lung, and Blood Institute
(NHLBI) has sponsored three important multicenter data
collection efforts: PTCA I (1977 to 1981, 3,000 patients);
PTCA II (1985 to 1986, 2,431 patients); and the New Ap-
proaches to Coronary Intervention (NACI) registry (1990 to
1994, 4,389 patients). Patients selected for PTCA in the PTCA
II versus PTCA I registry demonstrated a clear trend: in-
creased age, higher likelihood of multivessel disease, poorer
left ventricular function, higher rate of previous myocardial
infarction and increased lesion complexity (8). Nevertheless,
with the advances in balloon and angioplasty techniques, most
notably the development of steerable guide wires and improve-
ments in balloon catheter technology (the over the wire system,
lower balloon profiles, improved trackability, perfusion sys-
tems), PTCA results appeared to continue to maintain high
acute success rates despite increasing lesion complexity and
patient comorbidity. A recent comparison of PTCA data from
women in the PTCA II registry with a 500-woman component
of the NHLBI NACI registry from 1993 to 1994 confirmed the
improving clinical success rates of PTCA despite the higher
risk profile (9).
The PTCA registries were critical in establishing and vali-
dating the American College of Cardiology/American Heart
Association (ACC/AHA) scoring system, which allowed sys-
tematic characterization of stenoses for catheter-based ap-
proaches (10,11). The limitations of balloon angioplasty were
evident from these data, and the development of dozens of new
technologies followed.
In this issue of the Journal, the comparison by King et al.
(12) of the PTCA II and NACI registries continues the
previous trends. Importantly, this comparative study found no
superiority of the newer devices over PTCA when adjusted for
an elective setting and the overall higher level of illness in the
NACI cohort (12). Patient survival and freedom from target
lesion revascularization by catheter or surgeon were the same
in the two settings. It is a clinically important observation that
the onset of new technologies has allowed for treatment of
older patients with a higher rate of comorbidity, heart failure,
previous myocardial infarction and previous bypass while
maintaining a success rate similar to that of the PTCA II
database (12).
How does the NACI registry translate to today’s practice?
Even in the few years since the NACI registry ended enroll-
ment, the practice of interventional cardiology has evolved
dramatically. The limitations of comparing registries from
differing time frames make direct application to today’s prac-
tice difficult. Although the precise data are not known, there
has been a dramatic increase in the use of new single-device
procedures, such as rotational atherectomy (11.5% of NACI
registry patients examined), stenting (9.2%) and multiple-
device procedures (6.6%). The use of directional coronary
atherectomy (DCA) (30.6% of NACI patients examined) has
gone down significantly since the long-term results of the
randomized PTCA versus DCA trials were described (13,14).
The present study (12) examined only patients who under-
went revascularization with new devices in the NACI registry
as part of a elective or planned strategy. The entire NACI
registry included .4,000 patients, many of whom presented
with rescue stent procedures and acute myocardial infarction
and were not included in the present analysis. Despite the
more complex presentation of the entire NACI registry, high
procedural and lesion success rates were maintained (15).
Much of this success must be attributable to the advance of
catheter technologies. The use of stents in rescue situations—a
practice that has clearly changed the aggressiveness of balloon
angioplasty use as well as new devices—was exclusionary. One
would have to think that the use of stents in rescue situations
would affect direct comparisons of the technology. Given that
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the advent of stenting allows more aggressive balloon sizing
and dilation, the practice of PTCA during the NACI registry
era is different from the use of PTCA during the PTCA II
registry. This unavoidable confounder is further complicated
by the relatively ubiquitous use of stenting today.
Many centers report rates of stenting in catheter-based
intervention of 70% to 80%—a dramatic difference from the
NACI cohort. Additionally, the NACI stent data were col-
lected during an age of routine use of anticoagulation rather
than antiplatelet therapy. During the early 1990s, the use of
higher pressure stent deployment and intravascular ultra-
sound—techniques that appear to have an impact on overall
success rates—were not common. Clearly, stenting today is
safer and has a sustained improved outcome in combination
with current techniques and antiplatelet therapy (16–19). With
the release of newer stents with improved delivery character-
istics, lower profiles and greater flexibility, the use of coronary
stenting will increase as stent deployment approaches the ease
of simple balloon dilation.
The NACI data predated the use of new adjuvant therapies
that appear to be improving the acute and long-term results of
catheter-based techniques. The focus on the platelet as a key
agent in abrupt closure and restenosis (20,21), and the devel-
opment of platelet glycoprotein IIb/IIIa inhibitors appears to
be an area of great promise, as the experience with the
monoclonal antibody fragment abciximab (22,23) and tirofiban
(24) have borne out. The development of new antiplatelet
agents will see our present-day management evolve. Local
delivery of pharmacologic agents, including directed molecular
therapies, will continue to be explored and may have a great
impact (25–27). Catheter-based radiotherapy appears to im-
prove short-term outcomes when used in conjunction with
stenting in patients with restenosis (28).
The era of new devices in catheter-based revascularization
has seen headway made in treating restenosis, diffuse disease,
calcified lesions and reductions in abrupt closure. The lack of
a clear benefit with the NACI database emphasizes the need
for good clinical judgment in interventional decision making.
This dynamic is vitally important to maintain the momentum
that the “second-tier” devices have sustained since the ap-
proval of DCA in 1984. Procedures in complex lesions and high
risk patients that could not have been feasible a decade ago are
now considered routine. Unfortunately, randomized, con-
trolled clinical trials evaluating these devices as they are
released are logistically difficult, costly and obsolete by the
time of completion because of rapid device evolution during
the trial period. It is here that registry data are most valuable.
Although interventional cardiologists push the frontiers of
what and whom it is possible to treat by means of catheter-
based approaches with the use of new devices, it is clear that
there is much work to be done to improve the long-term
results.
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